A single residue, Lys108, of the delta-opioid receptor prevents the mu- opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor

M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh

Department of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.

Previously, we found that replacement of the region around the first extracellular loop of the delta-opioid receptor (OPR) with the corresponding region of the mu-OPR gives the high affinity for [D- Ala2,N-MePhe4,Gly-ol5]enkephalin (DAMGO), a mu-opioid-selective ligand, to the resultant chimeric receptor, DMDD, suggesting that the difference in the amino acid sequence within this region between the mu- and delta-OPRs is critical for the discrimination between these receptors by DAMGO. In the current study, we carried out systematic replacements of seven non-conserved residues in this region of the delta-OPR with the corresponding amino acid found in the mu-OPR. Among the seven mutant receptors, only one mutant receptor, delta K108N, showed high affinity (Ki = 18.68 +/- 5.27 nM) for DAMGO, which was comparable to that of the DMDD receptor (Ki = 23.77 +/- 4.27 nM) and 75- fold higher than that of the wild-type delta-OPR (Ki = 1405 +/- 161 nM). Lys108 in the delta-OPR was systematically replaced with 19 kinds of amino acids other than lysine. Among the resultant mutant receptors, 14 mutants bound DAMGO with Ki values comparable to those of the DMDD receptor, ranging from 4.20 to 43.38 nM. These findings suggest that Lys108 of the delta-OPR prevents DAMGO from binding to the delta-OPR rather than that the asparagine residue at the corresponding position in the mu-OPR is necessary for DAMGO binding. In addition, the replacement of Lys108 of the delta-OPR with asparagine dramatically increased the affinity for other peptidic mu receptor-selective ligands, such as dermorphin and D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2.

Volume 50, Issue 5, pp. 1413-1422, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				I. J. McFadyen, T. G. Metzger, M.G. Paterlini, and D. M. Ferguson Exploring the unique pharmacology of a novel opioid receptor, ZFOR1, using molecular modeling and the `message-address' concept Protein Eng. Des. Sel., December 1, 2001; 14(12): 953 - 960. [Abstract] [Full Text] [PDF]

				J. A. Schetz, P. S. Benjamin, and D. R. Sibley Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor Are Molecular Determinants of D4-Selective Pharmacology Mol. Pharmacol., January 1, 2000; 57(1): 144 - 152. [Abstract] [Full Text]

				R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]

				D. B. Fathy, S. A. Mathis, T. Leeb, and L. M. F. Leeb-Lundberg A Single Position in the Third Transmembrane Domains of the Human B1 and B2 Bradykinin Receptors Is Adjacent to and Discriminates between the C-terminal Residues of Subtype-selective Ligands J. Biol. Chem., May 15, 1998; 273(20): 12210 - 12218. [Abstract] [Full Text] [PDF]